--Nestle SA has started a process to sell its peanut-allergy treatment Palforzia, Bloomberg reports, citing unnamed sources.

--Initial bids are expected next month, but no final decision has been made on the timing of any sale, Bloomberg reports.

--Nestle, which bought the maker of Palforzia in a $2.6 billion deal in 2020 and recently announced a $2.1 billion impairment charge on the medication, declined to comment.

Full story: https://bloom.bg/3y2fmuv

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

March 02, 2023 03:27 ET (08:27 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Nestle (PK) (USOTC:NSRGY)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Nestle (PK).
Nestle (PK) (USOTC:NSRGY)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Nestle (PK).